Klaus Frueh
Präsident bei Tomegavax, Inc.
Profil
Klaus Frueh is the founder of Vir Biotechnology, Inc. which was founded in 2016.
He held the title of Director from 2016 to 2019.
Currently, Dr. Frueh is the President & Secretary at Tomegavax, Inc.
Aktive Positionen von Klaus Frueh
| Unternehmen | Position | Beginn |
|---|---|---|
Tomegavax, Inc.
 Tomegavax, Inc. Miscellaneous Commercial ServicesCommercial Services Tomegavax, Inc. provides health, science and drug services. It develops cures for AIDS, malaria, tuberculosis, herpes, papillomavirus and hepatitis-diseases where there’s no natural immunity in humans and traditional vaccine mechanisms don’t work. The company was founded in 2011 and is headquartered in Beaverton, OR. | Präsident | - |
Ehemalige bekannte Positionen von Klaus Frueh
| Unternehmen | Position | Ende |
|---|---|---|
| VIR BIOTECHNOLOGY, INC. | Gründer | 16.10.2019 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| VIR BIOTECHNOLOGY, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Tomegavax, Inc.
Tomegavax, Inc. Miscellaneous Commercial ServicesCommercial Services Tomegavax, Inc. provides health, science and drug services. It develops cures for AIDS, malaria, tuberculosis, herpes, papillomavirus and hepatitis-diseases where there’s no natural immunity in humans and traditional vaccine mechanisms don’t work. The company was founded in 2011 and is headquartered in Beaverton, OR. | Commercial Services |
